Affimed to Present at the Jefferies 2018 London Healthcare Conference

Heidelberg, Germany, November 8, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies that harness the power of innate and adaptive immunity (NK cells, macrophages and T cells), today announced that Dr. Adi Hoess, CEO, will present at the Jefferies 2018 London Healthcare Conference on Wednesday, November 14, 2018 at 8:40 am GMT in London.

A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK cells, macrophages and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

Affimed Media Contact:Anca Alexandru, Head of Communications, EU IRE-Mail: [email protected]

Affimed Investor Contact:Gregory Gin, Head of Investor RelationsE-Mail: [email protected]

Source: Affimed N.V.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• DPM Metals Announces Commercial Production at Vareš
• Pullner Reports Sustained Demand for Filtration Cartridges Across Power Generation Sector
• Vista Gold Appoints Gavin Ferguson as Managing Director, Vista Gold Australia